ORIGINAL ARTICLE

Health economic consequences of reducing salt intake and replacing saturated fat with polyunsaturated fat in the adult Finnish population: estimates based on the FINRISK and FINDIET studies

JA Martikainen^{1,2}, EJO Soini¹, DE Laaksonen³ and L Niskanen^{4,5}

¹ESIOR Oy Ltd, Kuopio, Finland; ²Pharmacoeconomics and Outcomes Research Unit, School of Pharmacy, University of Eastern Finland, Kuopio, Finland; ³Institute of Biomedicine, Physiology, University of Eastern Finland, Kuopio, Finland; ⁴Department of Medicine, Central Hospital of Central Finland, Jyväskylä, Finland and ⁵Faculty of Health Sciences, Department of Medicine, University of Eastern Finland, Kuopio, Finland

Background/Objectives: To predict the health economic consequences of modest reductions in the daily intake of salt (−1.0 g per day) and replacement of saturated fat (SFA, −1.0 energy percent (E%)) with polyunsaturated fat (PUFA, +1.0 E%) in the Finnish population aged 30–74 years.

Subjects/Methods: A Markov model with dynamic population structure was constructed to present the natural history of cardiovascular diseases (CVDs) based on the most current information about the age- and sex-specific cardiovascular risk factors, dietary habits and nutrient intake. To predict the undiscounted future health economic consequences of the reduction of dietary salt and SFA, the model results were extrapolated for the years 2010–2030 by replacing the baseline population in the year 2007 with the extrapolated populations from the official Finnish statistics. Finnish costs (€2009, societal perspective) and EQ-5D utilities were obtained from published references.

Results: During the next 20 years, a population-wide intervention directed at salt intake and dietary fat quality could potentially lead to 8000–13 000 prevented CVD cases among the Finnish adults compared the situation in year 2007. In addition, the reduced incidence of CVDs could gain 26 000–45 000 quality-adjusted life years and save €150–225 million over the same time period.

Conclusion: A modest reduction of salt and replacement of SFA with PUFA in food products can significantly reduce the burden of CVD in the adult Finnish population. This impact may be even larger in the near future due to the ageing of Finnish population.

European Journal of Clinical Nutrition (2011) **65**, 1148–1155; doi:10.1038/ejcn.2011.78; published online 18 May 2011

Keywords: salt; saturated fat; cardiovascular disease; cost-effectiveness; cost savings; dynamic modelling

Introduction

Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in industrialised countries, causing high health care utilisation costs. Elevated systolic blood pressure (SBP), total cholesterol (TC) and smoking are the

best known major risk factors of CVD (Vartiainen *et al.*, 2010). SBP (>115 mmHg) is the single most important cause responsible for >60% of strokes and ~50% of coronary heart disease events, whereas corresponding figures for elevated TC (>3.8 mmol/l) are around 20% and >50%, respectively (World Health Report, 2002).

The population-wide reduction in dietary salt and replacement of dietary saturated fat (SFA) with polyunsaturated fat (PUFA) are essential in reducing CVD incidence. Their importance is mediated at least in part by the effect of salt on blood pressure (BP) and dietary fat quality on total and

Correspondence: Dr JA Martikainen, ESIOR Oy Ltd, PO Box 1188, Mikrokatu 1, Kuopio FI-70211, Finland.

E-mail: janne.martikainen@esior.fi

Received 14 September 2010; revised 12 April 2011; accepted 12 April 2011; published online 18 May 2011

low-density lipoprotein cholesterol. The risk of CVD events increases progressively with increasing BP and cholesterol. The major portion of CVD deaths attributable to BP and cholesterol occurs in the upper range of 'normal' BP and TC levels (that is, BP > 130/80 mmHg and TC > 3.8 mmol/l; He and MacGregor, 2009).

In Finland, around 75% of the observed decline in coronary mortality in middle-aged men can be explained by decreases in BP, TC and smoking (Vartiainen *et al.*, 2010). Even though public health interventions aimed at these risk factors have dramatically decreased CVD disability and deaths in developed countries (He and MacGregor, 2009), CVD is still the most common cause of death, and stroke and acute myocardial infarction (MI) are major causes of disability. Despite marked changes in diet since the 1970s, average dietary intake of salt (8.4 g per day and 6.1 g per day for men and women, respectively) and SFA (12.7 E% per day for both sexes) are still above recommended levels (<5 g per day and <10 E%), with relatively low PUFA intake (World Health Organisation, 2007; Paturi *et al.*, 2008). Therefore, modest reduction of dietary salt and improvement of dietary fat quality, with even small shifts in the population distributions of SBP and TC towards lower values, may improve the health economic consequences of CVD substantially.

No detailed analyses on the economic consequences of reducing dietary salt and improving dietary fat quality intake have been carried out in the adult Finnish population. This study aims to predict the potential health economic consequences of moderate reduction of dietary salt combined with replacing some dietary SFA by PUFA. Owing to the data limitations, the analysis was restricted to Finns aged 30–74 years.

Subjects and methods

The year 2007 was selected as the baseline year for the CVD risk factors. A previously developed state transition Markov cohort model (Figure 1) for coronary heart disease (Martikainen *et al.*, 2007; Peura *et al.*, 2008) was enhanced by adding stroke and population components (Mar *et al.*, 2008). The new model was applied to estimate the incidence and prevalence of CVD events and mortality, impact on quality of life and associated costs in the adult Finnish population. First, the most current available national risk factor survey data (Peltonen *et al.*, 2008) and CVD risk functions (Vartiainen *et al.*, 2007) were incorporated into the Markov model. Second, an additional model component (Mar *et al.*, 2008) was built into the Markov model to estimate the total number of CVD patients in the Finnish population in 2007, and to make predictions for the years 2010–2030. Population estimates for adults aged ≥ 30 in year 2007 and population projections for years 2010–2030 were obtained from the official Finnish statistics. To predict the effects of risk-reducing interventions, expected numbers of events were extrapolated for the years 2010–2030 using the corresponding

Figure 1 Simplified structure of state transition model. The model included five health states and death, which was modelled as an absorbing terminal state. The 'healthy' state includes subjects without a history of myocardial infarction (MI) or stroke, and they have an annual probability of experiencing an initial non-fatal CVD event (MI or stroke), fatal event (non-CVD death or CVD death) or no CVD event.

annual extrapolated populations from Finnish statistics. All analyses were implemented in Microsoft Excel.

Event probabilities

For each 1-year cycle, the hypothetical cohort of men or women without established CVD were at risk of having of an acute non-fatal CVD event, a fatal CVD event, a fatal non-CVD event, or they might survive to the next year without suffering any event. The annual probabilities for CVD events were determined by logistic risk functions based on the FINRISK study (Vartiainen *et al.*, 2007). After each cycle, CVD risk factors were updated based on the Finnish age- and sex-specific risk factor profile data from the FINRISK 2007 survey (Peltonen *et al.*, 2008). As the FINRISK risk functions are developed to predict total CVD risk, information from the National Cardiovascular Disease Register (Laatikainen *et al.*, 2004) was used to determine the age- and gender-based case fatality. Annual risks of non-CVD deaths were estimated from the causes of death register by subtracting fraction of deaths due to CVDs from the total mortality. A more detailed description of the methods used to estimate the event probabilities is given in appendix.

The model was run until all subjects in the cohort entered into terminal states or until 75 years of age was reached. Because the FINRISK 2007 survey (Peltonen *et al.*, 2008) and its ancillary study FINDIET 2007 survey (Paturi *et al.*, 2008) did not include information about the levels of CVD risk factors for people aged 75 years and older, the target population was restricted to Finnish adults aged 30–74 to ensure the reliability of the model outcomes.

Health care resource use and costs

Costs, estimated from a societal perspective, included direct cost of prevention, morbidity, rehabilitation and production losses due to non-fatal CVD events. All costs were adjusted to

the 2009 price level using the official health care price index determined by the Association of Finnish Local and Regional authorities. All costs were also predicted as future financial streams over time to reflect the actual amount that the reduction of SFA and salt intake can be expected to save in a given year (Mauskopf *et al.*, 2007; Marshall *et al.*, 2008).

Annual age- and sex-specific costs (including costs of hospitalisation, outpatient care and prescribed outpatient medicines) associated with CVD events were obtained from reports based on the national discharge and prescription registries (Häkkinen *et al.*, 2007; Meretoja *et al.*, 2010). The model assumes that, after hospital discharge, subjects received a prescription for chronic coronary heart disease, dyslipidaemia or hypertension. Average drug treatment costs were weighted by the proportion of subjects receiving reimbursement for those medicines.

Costs of CVD rehabilitation were estimated by weighting the average rehabilitation costs obtained from the national rehabilitation registry at the Social Insurance Institution of Finland by the proportion (30–40%) of CVD patients receiving rehabilitation. Productivity losses due to non-fatal CVD events were estimated by multiplying the average length of sickness leave due to MI (4.78 months; Vehviläinen *et al.*, 2004) and stroke (8.11 months; Vohlonen *et al.*, 2002) by the average monthly income in Finland including payroll tax. Productivity losses were applied to patients below the average age of retirement, assumed to be 65 years. All unit cost estimates are summarised in Table 1.

Quality-adjusted life years

Age- and sex-specific quality of life estimates measured by generic EQ-5D instrument were used represent the average quality of life in the Finnish population aged 30–75 (Saarni *et al.*, 2006). The disutility weights due to initial or subsequent CVD events were determined from previously published studies (Saarni *et al.*, 2006; Lindgren *et al.*, 2007; Soini *et al.*, 2010).

Estimating the effectiveness of reduced salt and SFA intake on the number of CVD events and other outcomes

The reduction of 1 g of salt per day was assumed to change SBP approximately by -1.185 mmHg among hypertensive subjects and by -0.595 mmHg among normotensive subjects. These changes were estimated based on a dose-response relationship between the changes in dietary salt intake, 24-h urinary sodium and BP (He and MacGregor, 2003). These effect estimates were weighted by the age- and sex-specific proportions of hypertensive subjects (SBP > 130) in the Finnish population (Peltonen *et al.*, 2008). The effect of salt reduction on SBP was assumed to be linear over the range of 0–3 g per day (He and MacGregor, 2003).

Effects on serum TC of replacing SFA with PUFA were obtained from a meta-analysis of metabolic ward studies (Clarke *et al.*, 1997). Every 1% increase in energy (E%) from

PUFA intake was expected to lead to a -0.026 mmol/l change in TC and 0.005 mmol/l increase in high-density lipoprotein. Alternatively, the predicted changes in serum cholesterol were estimated by the Keys equation (Keys *et al.*, 1957), where 1 E% increase from PUFA was expected lead to around -0.043 mmol/l reduction in TC. The effect of changing BP and cholesterol levels on CVD events and deaths was then estimated using the FINRISK risk functions (Vartiainen *et al.*, 2007). To simplify the analysis, the full effect of dietary salt and SFA reduction was assumed to be achieved immediately and to persist during the whole time horizon.

Finally, the proportion of subjects receiving antihypertensive medication was assumed to change as a function of SBP. On the basis of an estimated logistic regression model, the reduction of 1 mmHg in SBP reduced the probability of receiving antihypertensive medication with adjustment for age, sex and body mass index, by $\sim 1.5\%$ in men and 2.8% in women (data on file).

Model calibration and sensitivity analyses

The model was calibrated to reproduce the number of key cardiovascular events among the 30–74 years old population in year 2007 in Finland. In addition, uncertainty associated with the model parameters was handled by determining probability distributions for all relevant parameters and then conducting probabilistic sensitivity analysis with 1000 iteration rounds (Briggs *et al.*, 2002). The selection of proper probability distributions for the model parameters has been described in details in technical appendix. The results of the probabilistic sensitivity analysis were used to determine 95% credibility intervals for the model outcomes and the probability of savings as a function of amount of savings. One-way sensitivity analyses were used to test the robustness of model assumptions.

Results

The model was calibrated by comparing the model results to the actual number of patient in the different health states in the year 2007. For example, according to the FINRISK 2007 study, the prevalence of people with history of stroke and MI is between 59 900–68 800 and 53 800–63 300 individuals among the Finnish population aged 30–74 years old, respectively (Peltonen *et al.*, 2008). The calibrated model estimated that the number of people with history of stroke is around 61 100 and the number of people with history of MI is $\sim 58 300$. Thus, on average, the calibrated model was considered to be sufficiently accurate to reproduce the baseline population for the year 2007.

Over 20 years, a population-wide intervention could potentially prevent 8000–13 000 CVD cases among the Finnish adults aged 30–74 compared with the status quo scenario, where the CVD risk factors stay at the year 2007 levels over time. In addition, the reduced incidence of CVD

Table 1 Parameters used in the model^a

	Point estimate		Source
	Men	Women	
<i>Utilities, mean (s.e.)</i>			
30–44	0.917 (0.003)	0.906 (0.003)	Estimated based on Saarni <i>et al.</i> (2006) and Soini <i>et al.</i> (2010)
45–54	0.876 (0.005)	0.865 (0.005)	
55–64	0.821 (0.006)	0.810 (0.006)	
65–74	0.781 (0.008)	0.770 (0.008)	
<i>Disutility due to CVD event, mean (s.e.)</i>			
Stroke	−0.145 (0.097)		Lindgren <i>et al.</i> (2007)
AMI	−0.092 (0.029)		Soini <i>et al.</i> (2010)
Post stroke	−0.090 (0.020)		Saarni <i>et al.</i> (2006)
Post MI	−0.011 (0.009)		Saarni <i>et al.</i> (2006)
<i>Costs, mean (s.e.)</i>			
Stroke, mean (s.e.) ^b	23 240€		Meretoja <i>et al.</i> (2010)
AMI			
30–44	16 245€ (762)	16 215€ (760)	Häkkinen <i>et al.</i> (2007)
45–54	14 955€ (701)	17 503€ (820)	
55–64	14 446€ (677)	16 326€ (765)	
65–74	12 995€ (609)	14 958€ (701)	
Fatal AMI ^c	2294€		Hujanen <i>et al.</i> (2008)
Rehabilitation after stroke (first year)	6182€		Assumption based on information from SII's database
Rehabilitation after MI (first year)	2576€		Assumption based on information from SII's database
Antihypertensive medication in the primary prevention per year	314	302	
Dyslipidaemia therapy in the primary prevention per year	195	166	
Monitoring a patient receiving antihypertensive medication	224€		Assumption based on SII data
Monitoring a patient receiving statins	185€		Assumption based on SII data
Monitoring a patient in secondary prevention	388€		Assumption based on SII data
Productivity losses due to non-fatal stroke	11 700€		Vohlonen <i>et al.</i> (2002)
Productivity losses due to non-fatal MI	6884€		Vehviläinen <i>et al.</i> (2004)

Abbreviations: AMI, acute myocardial infarction; CVD, cardiovascular disease; MI, myocardial infarction; SII, Social Insurance Institution of Finland (Kela).

^aCosts are presented in year 2009 values.

^bEstimate is a weighted average cost of treatment of ischemic stroke (79.4%), subarachnoid haemorrhage (13.6%) and intracerebral haemorrhage (7%).

^cA patient died during a hospitalisation.

cases could yield an additional 26 000–45 000 quality-adjusted life years and save 150–225 million Euros over the same time period. Detailed results of base case and additional one-way sensitivity analyses are presented in Table 2. Owing to the linearity assumption of effects, the approximations of outcomes with different reduction levels are easily extrapolated based on the results presented in Table 2. For example, reducing the daily intake of both dietary salt and SFA by 0.5 U would lead to around 74–113 million Euros savings during the next 20 years.

To take the uncertainty of model parameters into account, the probability of obtained cumulative savings was estimated. Figure 2 shows that in the base case scenario there is >95% chance that the cumulative total savings with and without productivity losses are at least 130 and 115 million Euros between the years 2010 and 2030, respectively. In addition, sensitivity analyses showed that the independent effect of salt reduction in the prevention of cardiovascular

events is larger than the effect of replacing SFA by PUFA (Table 2). The reduction of dietary salt is explained by >99% of changes in the incidence of CVD events and their consequences. However, when the Keys equation was used to predict the changes in TC, the reduction of dietary salt explained only around 62% the changes in the number of CVD cases. Thus, the interpretation of results needs to be carried out with care, as the results are sensitive to the selection of effect size estimates.

Discussion

Main findings of the study

This study demonstrated that even a modest reduction of dietary salt and replacement of dietary SFA with PUFA would have a great impact on the incidence of CVD events among the population aged 30–74 years. The lower number of CVD

Table 2 Predicted cumulative health and economic changes compared the situation in year 2007 between the years 2010 and 2030

Scenario	2010 Difference (95% CrI)	2020 Difference (95% CrI)	2030 Difference (95% CrI)
<i>Base case (salt -1 g, SFA -1 E%, PUFA +1 E%)</i>			
Non-fatal CVD	-215 (-348 to -97)	-2502 (-2944 to -2088)	-4752 (-5336 to -4185)
Fatal CVD	-137 (-296 to -60)	-1684 (-1980 to -1395)	-3271 (-3662 to -2897)
Cost (1000€)			
With productivity losses	-6786 (-11 506 to -2 926)	-70 507 (-84 489 to -57 924)	-147 094 (-167 364 to -128 731)
Without productivity losses	-5916 (-10 057 to -2 610)	-62 339 (-75 200 to -50 533)	-130 404 (-147 707 to -113 397)
QALYs gained	1105 (438 to 2 059)	13 444 (10 699 to 16 434)	26 255 (22 498 to 30 102)
<i>Base case with the Keys equation</i>			
Non-fatal CVD	-341 (-551 to -172)	-3930 (-4 612 to -3 286)	-7448 (-8372 to -6611)
Fatal CVD	-236 (-385 to -115)	-2833 (-3 298 to -2 363)	-5470 (-6152 to -4840)
Cost (1000€)			
With productivity losses	-10 425 (-17 098 to -5 022)	-107 996 (-127 347 to -89 659)	-224 785 (-252 792 to -197 489)
Without productivity losses	-8312 (-13 563 to -4 169)	-88 604 (-105 982 to -74 291)	-185 784 (-207 850 to -164 578)
QALYs gained	1907 (813 to 3409)	23 232 (18 723 to 28 291)	45 142 (38 586 to 52 421)
<i>Sensitivity analysis^a</i>			
<i>(-1.0 g of salt, -0.0 E% SFA)</i>			
Cost with productivity losses (1000€)	-6683	-69 923	-146 522
QALYs gained	1083	13 363	26 142
<i>Baseline risk of CVD event is decreased by -10%</i>			
Cost with productivity losses (1000€)	-6370	-66 830	-139 471
QALYs gained	1016	12 480	24 386
<i>Baseline risk of CVD event is increased by +10%</i>			
Cost with productivity losses (1000€)	-7158	-7389	-153 920
QALYs gained	1180	14 345	27 979

Abbreviations: CrI, credibility interval; CVD, cardiovascular disease; E%, energy percent; PUFA, polyunsaturated fat; QALYs, quality-adjusted life years; SFA, saturated fat.

^aOnly deterministic cost savings and QALYs gained are reported for one-way sensitivity analysis.

95% CrI are based on the Monte Carlo simulation.

Figure 2 Probability of cumulative savings (with and without productivity losses) given a dietary salt and saturated fat reduction of 1 g and 1 E% per day (base case scenario) among Finnish adults aged 30 to 74 between years 2010 and 2030. PL = productivity losses included.

events would result in substantial gains in quality-adjusted life years and cost savings.

The results of this study agree with previous studies (Selmer *et al.*, 2000; Murray *et al.*, 2003; Bibbins-Domingo *et al.*, 2010; Smith-Spangler *et al.*, 2010) that have demonstrated the potential benefits of salt reduction to reduce the burden of CVD. However, none of these previous studies have directly estimated the joint effects of reducing both salt and SFA intake simultaneously, considered here.

Strengths of the study

A strength of this study is that cardiovascular risk factors, dietary habits and nutrient intake of the Finnish population aged 30–74 years were obtained from a well-characterised and representative sample of Finnish adults (Paturi *et al.*, 2008; Peltonen *et al.*, 2008), and the cost and quality of life estimates were obtained from representative studies.

In the analysis, the independent role of dietary salt reduction of 1 g was larger than the role of a 1 E% change of SFA to PUFA. This is because both the effect sizes obtained from the literature differ and also the β -coefficients of FINRISK functions for the association of SBP with both CVD events and deaths are more significant than for the

corresponding association of serum TC with CVD cases. This is in part because serum TC is not included in the FINRISK function that predicts the risk of stroke. In contrast, SBP is a major risk factor for both stroke and MI. The analyses also assume that dietary fat quality mediates its effects on CVD risk solely via effects on lipids. However, dietary fat quality may influence CVD risk by mechanisms other than cholesterol (Erkkilä *et al.*, 2008), and the relatively strong inverse associations of PUFA intake and the PUFA/SFA ratio with coronary heart disease or CVD risk from some prospective cohort studies (Hu *et al.*, 1997; Laaksonen *et al.*, 2005; Erkkilä *et al.*, 2008) also implies that dietary fat quality impact cardiovascular risk more than would be predicted by effects on the lipid profile alone.

This study focused on replacement of SFA with PUFA. Because replacement of SFA with monounsaturated fat yields similar effects on the lipid profile (Clarke *et al.*, 1997), results would have been similar if monounsaturated or other unsaturated fat had been used in place of PUFA.

Limitations of the study

As the results of this study are based on statistical computer modelling requiring several assumptions, the results should be interpreted cautiously. This study did not specify any particular intervention aiming to reduce the dietary salt and SFA intake from daily food. However, the modest reductions presented here could be achieved by voluntary actions of the food industry aimed at a reducing the use of salt and SFA in processed food, a major source of dietary salt and SFA (Paturi *et al.*, 2008). There are already examples about successful strategies that have managed to reduce the intake of salt and SFA in cooperation with the food industry (Prättälä, 2003; Laatikainen *et al.*, 2006; Food Standard Agency, 2008; Pietinen *et al.*, 2008). These interventions, for example, have managed to reduce the intake of salt by 10–25% (Laatikainen *et al.*, 2006; Food Standard Agency, 2008).

We assumed no changes in consumer behaviour and persistence associated with these modifications, and dramatic changes in consumer behaviour would be unlikely, given that a reduction of dietary salt, for example, by 10–15% is possible without detection (Girgis *et al.*, 2003; Ruusunen and Puolanne, 2005). Moreover, after an adaptation period people appear to prefer food with less salt (Blais *et al.*, 1986).

To ensure the robustness of the study results, the study population was restricted to people aged 30–74 years. However, >50% of CVD cases occurs among the population aged ≥75 in Finland, so an important segment of the Finnish population could not be modelled. The impact in the whole population is, thus, clearly underestimated. However, at the moment there are no epidemiological data available to inform the association between CVD risk factors and the risk of CVD events among the elderly in Finland. The reduction of dietary salt and SFA is likely to benefit also

subjects aged <30 years, which will potentially decrease the future prevalence of hypertension and hyperlipidaemia in older age groups.

Moreover, there were no relevant estimates available for the proportion of patients provided assisted care or care in institutions such as nursing homes after non-fatal stroke or MI. Therefore, the cost of institutionalisation, which is especially important following stroke, has not been considered in the analysis. Also, potential changes in the number of patients with heart failure, end-stage renal disease or dementia (Kivipelto *et al.*, 2006; Solomon *et al.*, 2010) were not considered in the analysis due to the lack of data.

This analysis assumes that CVD risk factors stay at the same levels as they were in year 2007. However, if the declining trend in the levels of CVD risk factors seen in 1972–2007 (Vartiainen *et al.*, 2010) will continue unabated, the burden of CVD may not increase as much as presented in this study. On the other hand, the current epidemic of obesity and type II diabetes may have a negative impact on the trends seen in CVD incidence over the past several decades (Poirier *et al.*, 2006). Finally, the assumed linear relationships between salt and SFA intakes and SBP and TC may not hold, and there is evidence that reductions in BP could be even greater at lower levels of salt intake (Sacks *et al.*, 2001). An underestimate of the true amount of future cost savings and improved health at the population level may thus have resulted from these modelling assumptions.

Conclusion

Our findings suggest that even a modest reduction of dietary salt and replacement of SFA content with PUFA in food products can substantially reduce the total burden of CVDs in the adult Finnish population, with large cost savings from the societal point of view. The aging of the Finnish population may reinforce this impact.

Conflict of interest

JAM and EJOS are consultants and shareholders of ESiOR Oy, commissioned by HK Ruokatalo Oy to conduct this study; ESiOR also carried out commissioned studies and health economic analysis for several other pharmaceutical companies, food industry companies and hospitals. DEL and LN are internal medicine specialists at Kuopio University Hospital and act as medical advisors to ESiOR during the study. LN has held paid lectures and commercially sponsored research for MSD, Boehringer Ingelheim and AstraZeneca.

Acknowledgements

We thank nutrition specialist, MSc Soile Käkönen from HK Ruokatalo Oy for help during the study and PhD Christian

Asseburg for comments that helped us improve the manuscript. This study has been funded and supported by HK Ruokatalo Oy, Vantaa, Finland.

References

- Bibbins-Domingo K, Chertow G, Coxson P, Moran A, Lightwood J, Pletcher M *et al.* (2010). Projected effect of dietary salt reductions on future cardiovascular disease. *New Engl J Med* **362**, 590–599.
- Blais C, Pangborn R, Borhani N, Ferrell M, Prineas R, Laing B (1986). Effect of dietary sodium restriction on taste responses to sodium chloride: a longitudinal study. *Am J Clin Nutr* **44**, 232–243.
- Briggs AH, Goeree R, Blackhouse G, O'Brien BJ (2002). Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease. *Med Decis Making* **22**, 290–308.
- Clarke R, Frost C, Collins R, Appleby P, Peto R (1997). Dietary lipids and blood cholesterol: quantitative meta-analysis of metabolic ward studies. *Br Med J* **314**, 112–117.
- Erkkilä A, de Mello VDF, Riserus U, Laaksonen DE (2008). Dietary fatty acids and cardiovascular disease: an epidemiological approach. *Prog Lipid Res* **47**, 172–187.
- Food Standards Agency (2008). Dietary sodium levels surveys. Tuesday 22 July 2008. Available at <http://www.food.gov.uk/science/dietarysurveys/urinary> (accessed 2 March 2011).
- Girgis S, Neal B, Prescott J, Prendergast J, Dumbrell S, Turner C *et al.* (2003). A one-quarter reduction in the salt content of bread can be made without detection. *Eur J Clin Nutr* **57**, 616–620.
- He FJ, MacGregor GA (2009). A comprehensive review on salt and health and current experience of worldwide salt reduction programmes. *J Hum Hypertens* **23**, 363–384.
- He FJ, MacGregor GA (2003). How far should salt intake be reduced? *Hypertension* **42**, 1093–1099.
- Hu FB, Stamper MJ, Manson JAE, Rimm E, Colditz GA, Rosner BA *et al.* (1997). Dietary fat intake and the risk of coronary heart disease in women. *New Engl J Med* **337**, 1491–1499.
- Hujanen T, Kapiainen S, Tuominen U, Pekurinen M (2010). Terveystieteiden tutkimuskeskus Suomeksi vuonna 2006. Available at <http://www.stakes.fi/verkkosivut/tyopaperit/T3-2008-VERKKO.pdf> (10 June 2010).
- Häkkinen U, Idänpään-Heikkilä U, Keskimäki I, Klaukka T, Peltola M, Rauhala A *et al.* (2007). *PERFECT - Sydäinfarkti: Sydäinfarktin hoito, kustannukset ja vaikuttavuus*. Stakes: Helsinki.
- Keys A, Anderson JT, Grande F (1957). Prediction of serum cholesterol responses of man to changes in fat in the diet. *Lancet* **273**, 959–966.
- Kivipelto M, Ngandu T, Laatikainen T, Winblad B, Soininen H, Tuomilehto J (2006). Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study. *Lancet Neurol* **5**, 735–741.
- Laaksonen DE, Nyyssönen K, Niskanen L, Rissanen TH, Salonen JT (2005). Prediction of cardiovascular mortality in middle-aged men by dietary and serum linoleic and polyunsaturated fatty acids. *Arch Intern Med* **165**, 193–199.
- Laatikainen T, Pietinen P, Valsta L, Sundvall J, Reinivuo H, Tuomilehto J (2006). Sodium in the Finnish diet: 20-year trends in urinary sodium excretion among the adult population. *Eur J Clin Nutr* **60**, 965–970.
- Laatikainen T, Pääkkönen R, Keskimäki I, Hämäläinen H, Rintanen H, Niemi M *et al.* (2004). Tietokanta sepelvaltimotautien esiintyvyydestä. <http://www.ktl.fi/cvdr/>. *Fin Med J* **59**, 2403–2407.
- Lindgren P, Kahan T, Poulter N, Buxton M, Svarvar P, Dahlöf B *et al.* (2007). Utility loss and indirect costs following cardiovascular events in hypertensive patients: the ASCOT health economic substudy. *Eur J Health Econ* **8**, 25–30.
- Mar J, Sainz-Ezkerra M, Miranda-Serrano E (2008). Calculation of prevalence with Markov models: budget impact analysis of thrombolysis for stroke. *Med Decis Making* **28**, 481–490.
- Marshall D, Douglas P, Drummond M, Torrance G, MacLeod S, Manti O *et al.* (2008). Guidelines for conducting pharmaceutical budget impact analyses for submission to public drug plans in Canada. *Pharmacoeconomics* **26**, 477–495.
- Martikainen J, Ottelin A-M, Kiviniemi V, Gylling H (2007). Plant stanol esters are potentially cost-effective in the prevention of coronary heart disease in men: Bayesian modelling approach. *Eur J Cardiovasc Prev Rehabil* **14**, 265–272.
- Mauskopf JA, Sullivan SD, Annemans L, Caro J, Mullins CD, Nuijten M *et al.* (2007). Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices—budget impact analysis. *Value Health* **10**, 336–347.
- Meretoja A, Kaste M, Roine RO, Linna M, Juntunen M, Häkkinen U (2010). PERFECT Stroke – aivohalvauksen hoidon aiheuttamat suorat terveydenhuollon kustannukset Suomessa 1999 – 2008. National Institute for Health and Welfare, Avaus: Helsinki, February 2010.
- Murray C, Lauer J, Hutubessy R, Niessen L, Tomijima N, Rodgers A *et al.* (2003). Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk. *Lancet* **361**, 717–725.
- Paturi M, Tapanainen H, Reinivuo H, Pietinen P (eds) (2008). *The National FINDIET 2007 Survey*. National Public Health Institute B23/2008: Helsinki. Available at http://www.ktl.fi/attachments/suomi/julkaisut/julkaisusarja_b/2008/2008b23.pdf.
- Peltonen M, Harald K, Männistö S, Saarikoski L, Peltomäki P, Lund L *et al.* (2008). *Kansallinen FINRISKI 2007 -terveys tutkimus - Tutkimuksen toteutus ja tulokset* (in Finnish, tables, figures and summary in English) National Public Health Institute B34/2008: Helsinki. Available at <http://www.ktl.fi/attachments/finriski/2008b34.pdf> (accessed 10 June 2010).
- Peura P, Martikainen J, Soini E, Hallinen T, Niskanen L (2008). Cost-effectiveness of statins in the prevention of coronary heart disease events in middle-aged Finnish men. *Curr Med Res Opin* **24**, 1825–1834.
- Pietinen P, Valsta LM, Hirvonen T, Sinkko H (2008). Labelling the salt content in foods: a useful tool in reducing sodium intake in Finland. *Public Health Nutr* **11**, 335–340.
- Poirier P, Giles T, Bray G, Hong Y, Stern J, Pi-Sunyer FX *et al.* (2006). AHA scientific statement. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. *Circulation* **113**, 898–918.
- Prättälä R (2003). Dietary changes in Finland - success stories and future challenges. *Appetite* **41**, 245–249.
- Ruusunen M, Puolanne E (2005). Reducing sodium intake from meat products. *Meat Science* **70**, 531–541.
- Saarni SI, Härkänen T, Sintonen H, Suvisaari J, Koskinen S, Aromaa A *et al.* (2006). The impact of 29 chronic conditions on health-related quality of life: a general population survey in Finland using 15D and EQ-5D. *Qual Life Res* **15**, 1403–1414.
- Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D *et al.* (2001). Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. *N Engl J Med* **344**, 3–10.
- Selmer R, Kristiansen I, Haglerod A, Grsff-Iversen S, Larsen H, Meyer H *et al.* (2000). Cost and health consequences of reducing the population intake of salt. *J Epidemiol Community Health* **54**, 697–702.
- Smith-Spangler C, Juusola J, Enns E, Owens D, Garber A (2010). Population strategies to decrease sodium intake and the burden of cardiovascular disease. A cost-effectiveness analysis. *Ann Intern Med* **152**, 8481–8487.
- Soini E, Davies G, Martikainen J, Hu H, Tunceli K, Niskanen L (2010). Population-based health-economic evaluation of the secondary prevention of coronary heart disease in Finland. *Curr Med Res Opin* **26**, 25–36.

- Solomon A, Sippola R, Soininen H, Wolozin B, Tuomilehto J, Laatikainen T *et al.* (2010). Lipid-lowering treatment is related to decreased risk of dementia: a population-based study (FINRISK). *Neurodegener Dis* 7, 180–182.
- Vartiainen E, Laatikainen T, Peltonen M, Juolevi A, Männistö S, Sundvall J *et al.* (2010). Thirty-five-year trends in cardiovascular risk factors in Finland. *Int J Epidemiol* 39, 504–518.
- Vartiainen E, Laatikainen T, Salomaa V, Jousilahti P, Peltonen M, Puska P (2007). Sydäninfarkti- ja aivohalvausriskin arviointi FINRISKI-tutkimuksessa (The FINRISK function: estimation of the risk of coronary events and stroke in the Finnish population). *Fin Med J* 48, 4507–4513.
- Vehviläinen A, Hartikainen J, Niskanen L, Vohlonen I (2004). Työikäisten sepelvaltimotautipotilaiden hoidon kokonaiskustannukset (The costs of inpatient treatment of ischaemic heart disease patients). *Fin Med J* 3, 181–186.
- Vohlonen I, Vehviläinen A, Kinnunen J, Ihalainen R, Palmunen J, Lindroos K *et al.* (2002). Kuntien ja Kelan maksamat sairaalahoidon ja työstä poissaolon kustannukset. *Fin Med J* 24, 2675–2682.
- World Health Organisation (2007). *Reducing Salt Intake in Populations: Report of a WHO Forum and Technical Meeting, 5–7 October 2006, Paris, France*. World Health Organisation: Geneva, Switzerland.
- World Health Report (2002). *Reducing Risks, Promoting Healthy Life*. World Health Organisation: Geneva, Switzerland. Available at <http://www.who.int/whr/2002> (accessed 10 June 2010).

This work is licensed under the Creative Commons Attribution-NonCommercial-No Derivative Works 3.0 Unported License. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-nd/3.0/>

Supplementary Information accompanies the paper on European Journal of Clinical Nutrition website (<http://www.nature.com/ejcn>)